27 October 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2023 PBAC meeting are now available.

The MAESTrO Database has been updated accordingly (addition of (missing) information on patient populations, outcomes, comparators, clinical trials, type of economic evaluation, primary outcome, risk sharing agreement, link to Public Summary Document).

Insights will be added in the coming days. The team has already identified the following insights:

• The PBAC recommended the listing of nusinersen sodium (Spinraza) to include the pre-symptomatic initiation of nusinersen sodium in patients aged less than 36 months, genetically diagnosed with spinal muscular atrophy, who have a survival motor neuron 2 gene copy number of 3, it did not recommend expanding the listing for pre-symptomatic initiation of nusinersen sodium to patients aged from 36 months to under 18 years of age.
• The PBAC recommended the PBS listing of lumacaftor with ivacaftor (Orkambi) for patients aged 1 to less than 2 years with cystic fibrosis who are homozygous for the F580del mutation in the cystic fibrosis transmembrane conductance regulator gene, to include even though the 'PBAC considered that the base case incremental cost effectiveness ratio was uncertain.'
• The PBAC did not recommend the listing of esketamine hydrochloride (Spravato) for the treatment of patients with treatment resistant depression because its cost effectiveness is uncertain. 'The PBAC considered it was unlikely that esketamine hydrochloride would be cost effective if additional courses of treatment were required within the 5-year period.'

Read PBS News